Phocas Financial Corp. Cuts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Phocas Financial Corp. lessened its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 22.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 121,559 shares of the specialty pharmaceutical company's stock after selling 35,507 shares during the quarter. Phocas Financial Corp. owned 0.22% of Supernus Pharmaceuticals worth $3,518,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Supernus Pharmaceuticals by 96.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,401 shares of the specialty pharmaceutical company's stock valued at $39,000 after acquiring an additional 687 shares in the last quarter. Public Employees Retirement System of Ohio raised its position in Supernus Pharmaceuticals by 41.6% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 1,253 shares of the specialty pharmaceutical company's stock worth $42,000 after purchasing an additional 368 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Supernus Pharmaceuticals by 389.7% during the 1st quarter. Tower Research Capital LLC TRC now owns 1,327 shares of the specialty pharmaceutical company's stock worth $48,000 after purchasing an additional 1,056 shares during the last quarter. Point72 Middle East FZE bought a new position in Supernus Pharmaceuticals during the 4th quarter worth $57,000. Finally, Covestor Ltd raised its position in Supernus Pharmaceuticals by 115.0% during the 3rd quarter. Covestor Ltd now owns 2,350 shares of the specialty pharmaceutical company's stock worth $65,000 after purchasing an additional 1,257 shares during the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 3,884 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $32.99, for a total value of $128,133.16. Following the completion of the transaction, the vice president now directly owns 8,570 shares of the company's stock, valued at approximately $282,724.30. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, VP Padmanabh P. Bhatt sold 5,000 shares of the business's stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $30.21, for a total value of $151,050.00. Following the completion of the sale, the vice president now directly owns 8,570 shares of the company's stock, valued at approximately $258,899.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Padmanabh P. Bhatt sold 3,884 shares of the business's stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $32.99, for a total value of $128,133.16. Following the completion of the sale, the vice president now directly owns 8,570 shares of the company's stock, valued at $282,724.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 35,739 shares of company stock valued at $1,227,433. Corporate insiders own 8.76% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Piper Sandler lowered their target price on Supernus Pharmaceuticals from $45.00 to $41.00 and set an "overweight" rating for the company in a research report on Wednesday, February 28th.

Supernus Pharmaceuticals Stock Down 0.8 %

NASDAQ:SUPN traded down $0.25 during trading hours on Monday, hitting $29.99. 372,719 shares of the company were exchanged, compared to its average volume of 385,050. Supernus Pharmaceuticals, Inc. has a one year low of $21.99 and a one year high of $39.09. The company has a fifty day simple moving average of $31.17 and a 200 day simple moving average of $28.47.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.41 by ($0.39). Supernus Pharmaceuticals had a return on equity of 0.14% and a net margin of 0.22%. The business had revenue of $164.30 million during the quarter, compared to the consensus estimate of $155.03 million. During the same period last year, the business posted $0.43 earnings per share. The business's revenue was down 1.8% on a year-over-year basis. Analysts predict that Supernus Pharmaceuticals, Inc. will post 1.16 earnings per share for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.